Trial Profile
A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferitazole (Primary)
- Indications Iron overload
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors FerroKin BioSciences; Shire
- 20 Oct 2014 New trial record